Hologic Scores Well in Brachtherapy Trial

Zacks

Hologic, Inc. (HOLX), announced the final analysis results of the MammoSite Breast Brachytherapy Registry Trial data, released by the American Society of Breast Surgeons (:ASBS).The company reaffirmed that the analysis confirms previously noted "excellent" results which fare favorably when compared with other forms of accelerated partial breast irradiation (:APBI) and whole breast irradiation.

The study described Hologic's MammoSite Radiation Therapy as one of the most patient friendly treatment options, enabling women to return to their regular lives after five days of treatment, simultaneously reducing the side effects.

The healthcare professionals who were part of the team that conducted the study also welcomed the successful results. They believe that eventually, their will be a global rise in the choice of accelerated partial breast irradiation as an effective treatment option, among women suffering from breast cancer.

MammoSite Therapy, is a form of targeted radiation therapy that can be applied directly to the area where cancer is most likely to recur. It allows the entire radiation course to be completed within a mere five days as compared to the regular five to seven weeks. Moreover, the targeted therapy of the breast limits radiation exposure to normal and healthy tissue minimizing side effects such as skin discoloration, scarring, burning, fatigue and damage to the surrounding organs.

Equipped with a multi-lumen design, the MammoSite ML system provides radiation oncologists the flexibility to adjust the radiation dose as per the requirement of every individual case. It also allows the oncologists to treat such patients who are not suitable for traditional brachytherapy.

MammoSite Registry Trial as undertaken by the American Society of Breast Surgeons (:ASBS) covered 1400 early–stage breast cancer patients over a span of seven years. These patients had undergone breast conserving therapy treatment using Hologic's MammoSite targeted radiation therapy system, between May 2002 and Jun 2004.

Low rates of local recurrence as well as low levels of toxicity post treatment were some of the positive outcomes as stated by the ASBS. The reduced treatment time and the safety and efficacy of brachytherapy-based partial breast irradiation score much higher when rated against other conventional whole breast irradiation systems.

The final analysis results were published online in advance of print in the Aug 22, 2013 issue of the Annals of Surgical Oncology. HOLX was pleased to receive such positive feedback from the highly regarded American Society of Breast Surgeons and hopes to bring forth more such revolutionary treatment solutions for the betterment of women healthcare around the world.

Currently, HOLX carries a Zacks Rank #3 (Hold). Other medical instruments stocks that are worth a look include Delcath Systems, Inc. (DCTH), Echo Therapeutics, Inc. (ECTE) and Given Imaging Ltd. (GIVN), each carrying a Zacks Rank #2 (Buy).

Read the Full Research Report on HOLXRead the Full Research Report on GIVNRead the Full Research Report on DCTHRead the Full Research Report on ECTEZacks Investment Research

Rates

View Comments (0)